Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and ...

A slow immune response to SARS-CoV-2 infection, delayed viral clearance, and viral rebound can all increase a person’s risk ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from in-person to virtual due to the COVID-19 pandemic. On the fifth anniversary ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

The Phase 1 study data showed that the two different formulations of once-yearly lenacapavir administered via intramuscular injection achieved and maintained plasma concentrations exceeding those ...

Theratechnologies (THTX) presented data highlighting the limitations of using body mass index alone in assessing cardiovascular risk in people ...